VK Sharma of HDFC Securities told CNBC-TV18, “In the coming few years if one has a two or three year horizon the growth in Sun Pharmaceutical Industries will come from its subsidiaries, the acquisitions which it has done in the past. Taro Pharmaceutical will disappoint next year but the other two subsidiaries URL Pharma and DUSA Pharmaceuticals should invariably help. Also its own subsidiary, the research outfit Sun Pharma Advanced Research Company (SPARC) has also begun contributing and will also contribute more.”
He further added, “One can continue to hold Sun Pharma. However, if one needs to add more then the addition can be done in SPARC, which will grow at a much faster pace than Sun itself and mind you that is a very high risk venture. So, if you want safety you can average in Sun Pharmaceutical Industries but if you want high risk and high returns SPARC will give you better returns.”
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
